Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
Abstract Background Visfatin is an adipokine that related with the inflammation in atherosclerosis and the destabilization of atherosclerotic plaque. The aim of this study was to observe the relationship between visfatin and major adverse cardiovascular events (MACEs) in acute myocardial infarction...
Main Authors: | Meifan Zheng, Nan Lu, Meixia Ren, Haifeng Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-020-01549-3 |
Similar Items
-
Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis
by: Yifang Zhou, et al.
Published: (2023-08-01) -
Correlations of visfatin with severity of acute myocardial infarction, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention
by: Zhang Huihui, et al.
Published: (2023-01-01) -
Predictive Model for Long-term Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention
by: Qin LI, Xin TAN, Wenxi JIANG, Meng YUAN, Hui NI, Yuan WANG, Jie DU
Published: (2022-08-01) -
Comparison of In-hospital Major Adverse Cardiovascular Events in Patients of Acute Inferior Myocardial Infarction With or Without Precordial ST Segment Depression
by: Jaya Suganti, et al.
Published: (2017-04-01) -
Managed Care after Acute Myocardial Infarction (KOS-zawał) reduces major adverse cardiovascular events by 45% in 3-month follow-up – single-center results of Poland’s National Health Fund program of comprehensive post-myocardial infarction care
by: Krystian Wita, et al.
Published: (2019-06-01)